The role of collateral related donors in haploidentical hematopoietic stem cell transplantation

被引:27
|
作者
Mo, Xiao-Dong [1 ]
Zhang, Yuan-Yuan [1 ]
Zhang, Xiao-Hui [1 ]
Xu, Lan-Ping [1 ]
Wang, Yu [1 ]
Yan, Chen-Hua [1 ]
Chen, Huan [1 ]
Chen, Yu-Hong [1 ]
Chang, Ying-Jun [1 ]
Liu, Kai-Yan [1 ]
Huang, Xiao-Jun [1 ,2 ,3 ]
机构
[1] Peking Univ, Peoples Hosp, Inst Hematol, Beijing 100044, Peoples R China
[2] Peking Tsinghua Ctr Life Sci, Beijing 100871, Peoples R China
[3] Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100044, Peoples R China
基金
中国国家自然科学基金;
关键词
Haploidentical; Hematopoietic stem cell transplantation; Collateral related donors; Paternal donors; Maternal donors; VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; IDENTICAL-SIBLING TRANSPLANT; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CHRONIC GRAFT; HEMATOLOGICAL MALIGNANCIES; UNRELATED DONORS; SINGLE-CENTER; RISK-FACTORS;
D O I
10.1016/j.scib.2018.08.008
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
A key issue in the haploiedntical hematopoietic stem cell transplantation (haplo-HSCT) setting is the search for the best donor, because donor selection can significantly impact the clinical outcomes. We aimed to identify the role of collateral related donors (CRDs) in donor selection for haplo-HSCT through comparing the clinical outcomes between CRDs (n = 60) and maternal donors (MDs, n = 296), which were the last choice of donor selection in immediate related donors (IRDs). The cumulative incidence of graft-versus-host disease was comparable between CRDs and MDs. The 5-year cumulative incidence of relapse and non-relapse mortality was 22.0% (95% CI, 11.3%-32.7%) versus 17.4% (95% CI, 13.0%-21.8%) (P = 0.455) and 25.0% (95% CI, 13.9%-36.1%) versus 23.1% (95% CI, 18.2%-28.0%) (P = 0.721) for the CRDs and MDs, respectively. The 5-year probabilities of disease-free survival and overall survival was 53.2% (95% CI, 40.4%-66.0%) versus 59.5% (95% CI, 53.8%-65.2%) (P = 0.406) and 56.5% (95% CI, 43.8%-69.2%) versus 61.8% (95% CI, 56.1%-67.5%) (P = 0.458) for the CRDs and MDs, respectively. Female donor/male recipient (FDMR) CRDs were associated with the poorest clinical outcomes, and the clinical outcomes of non-FDMR CRDs were comparable to those of MDs. In summary, our results showed that CRDs did not showed superiority over MDs. Thus, IRDs should be the first choice of donor selection, and CRDs could only be the donors for those without IRDs. (C) 2018 Science China Press. Published by Elsevier B.V. and Science China Press. All rights reserved.
引用
收藏
页码:1376 / 1382
页数:7
相关论文
共 50 条
  • [21] Hematopoietic stem cell transplantation for homozygous β-thalassemia and β-thalassemia/hemoglobin E patients from haploidentical donors
    U Anurathapan
    S Hongeng
    S Pakakasama
    N Sirachainan
    D Songdej
    A Chuansumrit
    P Charoenkwan
    A Jetsrisuparb
    K Sanpakit
    P Rujkijyanont
    A Meekaewkunchorn
    Y Lektrakul
    P Iamsirirak
    P Surapolchai
    W Satayasai
    S Sirireung
    R Sruamsiri
    P A Wahidiyat
    A Ungkanont
    S Issaragrisil
    B S Andersson
    Bone Marrow Transplantation, 2016, 51 : 813 - 818
  • [22] Hematopoietic stem cell transplantation for homozygous β-thalassemia and β-thalassemia/hemoglobin E patients from haploidentical donors
    Anurathapan, U.
    Hongeng, S.
    Pakakasama, S.
    Sirachainan, N.
    Songdej, D.
    Chuansumrit, A.
    Charoenkwan, P.
    Jetsrisuparb, A.
    Sanpakit, K.
    Rujkijyanont, P.
    Meekaewkunchorn, A.
    Lektrakul, Y.
    Iamsirirak, P.
    Surapolchai, P.
    Satayasai, W.
    Sirireung, S.
    Sruamsiri, R.
    Wahidiyat, P. A.
    Ungkanont, A.
    Issaragrisil, S.
    Andersson, B. S.
    BONE MARROW TRANSPLANTATION, 2016, 51 (06) : 813 - 818
  • [23] Allogeneic hematopoietic stem cell transplant using Mismatched/Haploidentical donors
    Koh, Liang-Piu
    Rizzieri, David A.
    Chao, Nelson J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (11) : 1249 - 1267
  • [24] A Teleconference With Related Donors Years After Allogeneic Hematopoietic Stem Cell Transplantation
    Aydogan, Merve
    Yuksel, Merve
    Akal, Filiz
    Yuksel, Meltem Kurt
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2024, 22 (07) : 559 - 567
  • [25] Natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation
    Ruggeri, L
    Capanni, M
    Mancusi, A
    Perruccio, K
    Burchielli, E
    Martelli, ME
    Velardi, A
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2005, 81 (01) : 13 - 17
  • [26] Natural Killer Cell Alloreactivity in Haploidentical Hematopoietic Stem Cell Transplantation
    Loredana Ruggeri
    Marusca Capanni
    Antonella Mancusi
    Katia Perruccio
    Emanuela Burchielli
    Massimo F. Martelli
    Andrea Velardi
    International Journal of Hematology, 2005, 81 : 13 - 17
  • [27] Haploidentical Hematopoietic Stem Cell Transplantation for Relapsed Metastatic Retinoblastoma
    Rastogi, Neha
    Kapoor, Rohit
    Yadav, Satya P.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2020, 42 (08) : 499 - 499
  • [28] Immunity to Infections after Haploidentical Hematopoietic Stem Cell Transplantation
    Aversa, Franco
    Prezioso, Lucia
    Manfra, Ilenia
    Galaverna, Federica
    Spolzino, Angelica
    Monti, Alessandro
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2016, 8
  • [29] Graft Failure after Haploidentical Hematopoietic Stem Cell Transplantation
    Hickey, Cindy Lynn
    Kim, Haesook T.
    Nikiforow, Sarah
    Gooptu, Mahasweta
    Koreth, John
    Ritz, Jerome
    Ho, Vincent T.
    Alyea, Edwin P., III
    Soiffer, Robert J.
    Antin, Joseph H.
    Cutler, Corey
    Romee, Rizwan
    BLOOD, 2019, 134
  • [30] Update on current research into haploidentical hematopoietic stem cell transplantation
    Sun, Yu-Qian
    Chang, Ying-Jun
    Huang, Xiao-Jun
    EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (04) : 273 - 284